Study summary
Half of men on enzalutamide were alive 8 years later
50%alive at 8 years, vs 40% with the older drug
What was tested
Enzalutamide against an older antiandrogen, both with testosterone suppression, for metastatic hormone-sensitive prostate cancer.
What they found
- Median overall survival was 7.9 vs 5.8 years.
- Most men stayed on the full dose; serious heart and nerve side effects were similar.
What it means
Shows how far survival has come with modern hormone therapy started at diagnosis.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.